KANSAS CITY, Kan. and BOSTON, Nov. 19, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it will present at the Jefferies 2013 London Healthcare Conference, to be held November 20-21, 2013, in London, UK, and at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York.
Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences.
Event:Jefferies 2013 London Healthcare ConferenceDate: Thursday, November 21, 2013 Time: 10:00 am (Greenwich Mean Time) Location:London, UK
Event:Piper Jaffray 25th Annual Healthcare ConferenceDate: Wednesday, December 4, 2013 Time: 1:30 pm (Eastern Time)Location:New York, NY
The presentations will be webcast live and remain available for two weeks following the presentation. To access the webcasts, please visit the investor relations section of the Aratana website at aratana.investorroom.com.
About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
email@example.com; (212) 375-2664
Andrew Mielach (media)
firstname.lastname@example.org; (212) 375-2694
|SOURCE Aratana Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved